May 07, 2021 09:17 AM (GMT+8) · EqualOcean
Yaoming bio announced today that it has completed three acquisitions of Bayer's stock solution production base in Wuppertal, Germany, Pfizer China's stock solution and preparation production base in Hangzhou, and Suqiao bio, a Chinese biopharmaceutical contract R & D and production enterprise (cdmo). GMP production will be started in the original liquid and preparation production bases purchased above within this year. It is estimated that by the end of 2021, Yaoming bio will operate 11 stock solution plants in China, the United States and Germany, and the total capacity of stock solution will rapidly rise to 150000 liters.